Format

Send to

Choose Destination
Blood Cancer J. 2015 Oct 2;5:e351. doi: 10.1038/bcj.2015.77.

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Author information

1
Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
PMID:
26430722
PMCID:
PMC4635189
DOI:
10.1038/bcj.2015.77
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center